Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 20, 2023 08:00 ET | Source: ImPact Biotech

ImPact Biotech Receives FDA Clearance of IND Application for Padeliporfin VTP in Pancreatic Cancer

Phase 1 clinical trial expected to initiate in 1H 2024 –IND clearance in third indication reflects broad platform potential for Padeliporfin VTP across a range of solid tumors – TEL AVIV, Israel,...
December 18, 2023 14:53 ET | Source: ImPact Biotech

ImPact Biotech Announces Appointment of Eyal Morag, M.D. as Chief Medical Officer

TEL AVIV, Israel, Dec. 18, 2023 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy to treat a...
August 13, 2023 16:16 ET | Source: ImPact Biotech

ImPact Biotech Announces Research Collaboration to develop a treatment to arrest Pathologic Myopia using its Padeliporfin minimally invasive platform

ImPact Biotech to collaborate with Maastricht University researchers to develop a treatment to arrest the progressive condition Pathologic Myopia, a leading cause of irreversible sight impairment and...
August 04, 2023 10:49 ET | Source: ImPact Biotech

ImPact Biotech receives FDA Clearance for Padeliporfin VTP Phase 1 Clinical Program in Peripheral Lung Cancer

Padeliporfin VTP Phase 1 trial in Peripheral Non-Small Cell Lung Cancer to start by end Q4 2023 TEL AVIV, Israel, Aug. 04, 2023 (GLOBE NEWSWIRE) -- ImPact Biotech,...
July 05, 2023 09:44 ET | Source: ImPact Biotech

ImPact Biotech receives FDA Orphan Drug Designation for Padeliporfin VTP in Pancreatic Cancer

Designation confers advantages including marketing exclusivity and tax credits Padeliporfin VTP Phase 1 trial in Pancreatic cancer to start by end Q4 2023 TEL AVIV, Israel, July 05, 2023 (GLOBE...